Apparent Diffusion Coefficient Histogram Analysis Stratifies Progression-Free Survival in Newly Diagnosed Bevacizumab-Treated Glioblastoma

Antiangiogenesis Treatment for Glioblastoma Multiforme: Challenges and Opportunities

(2017) Eric T. Wong et al.   Journal of the National Comprehensive Cancer Network

Randomized Double-Blind Placebo-Controlled Trial of Bevacizumab Therapy for Radiation Necrosis of the Central Nervous System

(2010) Victor A. Levin et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

(2010) Patrick Y. Wen et al.   JOURNAL OF CLINICAL ONCOLOGY

Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity

(2010) Benjamin M. Ellingson et al.   JOURNAL OF MAGNETIC RESONANCE IMAGING

Acquired Resistance to Temozolomide in Glioma Cell Lines: Molecular Mechanisms and Potential Translational Applications

(2010) Jihong Zhang et al.   ONCOLOGY

Changes of the O6-methylguanine-DNA methyltransferase promoter methylation and MGMT protein expression after adjuvant treatment in glioblastoma

(2010) Jung   ONCOLOGY REPORTS

Pseudoprogression and pseudoresponse: Challenges in brain tumor imaging

(2009) Jennifer L. Clarke et al.   Current Neurology and Neuroscience Reports

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

(2009) Henry S. Friedman et al.   JOURNAL OF CLINICAL ONCOLOGY

Antiangiogenic therapies for high-grade glioma

(2009) Andrew D. Norden et al.   Nature Reviews Neurology

An analysis of image texture, tumor location, and MGMT promoter methylation in glioblastoma using magnetic resonance imaging

(2009) Sylvia Drabycz et al.   NEUROIMAGE

Recurrent Glioblastoma Multiforme: ADC Histogram Analysis Predicts Response to Bevacizumab Treatment

(2009) Whitney B. Pope et al.   RADIOLOGY

Pseudoprogression in Glioblastoma

(2008) Marc C. Chamberlain   JOURNAL OF CLINICAL ONCOLOGY

MGMTPromoter Methylation Status Can Predict the Incidence and Outcome of Pseudoprogression After Concomitant Radiochemotherapy in Newly Diagnosed Glioblastoma Patients

(2008) Alba A. Brandes et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma

(2008) Teri N. Kreisl et al.   JOURNAL OF CLINICAL ONCOLOGY

Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization

(2008) A. Claes et al.   MOLECULAR CANCER THERAPEUTICS